



an Open Access Journal by MDPI

Diagnostic and Therapeutic Advances in Retinal Disease

Guest Editors:

Prof. Dr. Randolph D. Glickman

Department of Ophthalmology,
University of Texas Health
Science Center at San Antonio,
San Antonio, TX, USA

Dr. Igor O. Nasonkin

Department of Ophthalmology,
Louis J. Fox Center for Vision
Restoration, University of
Pittsburgh Medical Center,
Pittsburgh, PA, USA

Deadline for manuscript
submissions:

27 September 2024

Message from the Guest Editors

Dear Colleagues,

Degenerative diseases of the retina continue to be a leading cause of vision loss. Further advances in the treatment of retinal degeneration will require a deeper understanding of the molecular pathophysiology of these diseases. This Special Issue will promote this goal by highlighting notable advances in the diagnosis and therapy of retinal degenerative (RD) disease. In the area of retinal disease diagnosis, contributions are invited that feature innovations and advances in such areas as molecular diagnostics, imaging, applications of artificial intelligence or informatics to assist in complex diagnoses, and innovative approaches that are based on multifactorial diagnostic indicators. Gene therapies, neuroprotection, in vivo gene editing, retinal replacement, regeneration, immunomodulation, and therapeutic monoclonal antibody modalities to managing the RD diseases are all welcome in this Special Issue.

- Cell therapy
- Gene therapy
- Neuroprotection
- Regeneration
- Retinal ganglion cells
- Retinal pigment epithelium
- Therapeutic antibodies
- Vision restoration



mdpi.com/si/84471

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI